Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall discussions reflect a positive perception of small molecules in cancer treatment, emphasizing their advantages like targeted action, safety, and regulatory approval, with phrases like 'high potency and low toxicity' indicating recognition of their importance, but without extensive critical analysis or detailed exploration of ongoing challenges.
The posts generally agree with the idea that small molecules are beneficial and have gained approval due to their efficacy and safety, reflecting a positive stance.
Posts express a moderate interest, highlighting developments and approvals, but lack deeper curiosity or critique.
The discussions briefly touch on clinical implications and approval processes, indicating some engagement with the topic but not in-depth analysis.
The posts acknowledge the significance of small molecules in cancer therapy, suggesting they are impactful within the medical and research community.
@iluminatibot Small molecules in targeted cancer therapy: advances, challenges, and future perspectives Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine
@iluminatibot Small molecules in targeted cancer therapy: advances, challenges, and future perspectives Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives https://t.co/sodnQ5YWQO
Small molecules as cancer therapy:) Small molecules that target cancerous tumor cells but spare normal cells, additionally, having high potency and low toxicity; hence, get the FDA approval in the past 20 years. #fda#KAIMARC https://t.co/FfhcrV2IAi https://t.co/OpTz5iHF27
Since 2001, small-molecule targeted drugs have seen significant progress in cancer treatment, with 89 approved by 2020. Despite successes, challenges like low response rates and drug resistance remain significant…
Since 2001, significant progress has been made in developing small-molecule targeted drugs for cancer treatment, with 89 approved by major regulatory bodies by 2020. Despite these advancements, challenges like low…
Since imatinib's approval in 2001, significant progress has been made in developing small-molecule targeted drugs for cancer treatment, with 89 approved by 2020. The video discusses drug targets, clinical trials, and…
Since the approval of imatinib in 2001, significant progress has been made in developing small-molecule targeted drugs for cancer treatment. Despite this, challenges such as low response rates and drug resistance…
@iluminatibot Small molecules in targeted cancer therapy: advances, challenges, and future perspectives Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine
@iluminatibot Small molecules in targeted cancer therapy: advances, challenges, and future perspectives Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine
Small molecules as cancer therapy:) Small molecules that target cancerous tumor cells but spare normal cells, additionally, having high potency and low toxicity; hence, get the FDA approval in the past 20 years. #fda#KAIMARC https://t.co/FfhcrV2IAi https://t.co/OpTz5iHF27
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives https://t.co/sodnQ5YWQO